Global experience with ixabepilone in breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 5, 2011, Pages 683-692

  Kaklamani, Virginia G ^a   Xu, Binge H ^b   Gomez, Henry L ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CANCER HOSPITAL   (China)

^c INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

anthracyclines; ethnic groups; global; ixabepilone; pretreatment; resistance; taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; IXABEPILONE; KETOCONAZOLE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; HAND FOOT SYNDROME; HEALTH CARE AVAILABILITY; HUMAN; INFECTION; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; STOMATITIS; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG APPROVAL; EPOTHILONES; ETHNIC GROUPS; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH;

EID: 79955810347     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.41     Document Type: Article

References (61)

1. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch. Intern. Med. 163(1), 49-56 (2003).
2. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. Miller BA, Kolonel LN, Bernstein L et al. (Eds). National Cancer Institute, Bethesda, MD, USA, NIH publication no. 96-4104 (1996).
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER) -negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype a population-based study from the California Cancer Registry. Cancer 109(9), 1721-1728 (2007).
4. Stark A, Kleer CG, Martin I et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 116(21), 4926-4932 (2010).
5. Vallejos CS, Gomez HL, Cruz WR et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clin. Breast Cancer 10(4), 294-300 (2010).
6. Lee R, Mayer K, Dranitsaris G, Verma S. Breast cancer trials: is race an important factor? AS CO Breast Cancer Symposium (2009) (Abstract 139). Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J. Epidemiol. Community Health 58(6), 411-415 (2004).
7. Ng PC, Zhao Q, Levy S, Strausberg RL, Venter JC. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther. 84(3), 306-309 (2008).
8. Suarez-Kurtz G. The implications of population admixture in race-based drug prescription. Clin. Pharmacol. Ther. 83(3), 399-400 (2008).
9. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. DrugMetab. Toxicol. 5(3), 243-257 (2009).
10. Rodriguez Jimenez P. [Blood and mestizaje in Spanish America]. Anuario Colombiano de Historia Socialy de la Cultura 35, 279-309 (2008).
11. Simon SD, Bines J, Barrios CH et al. Clinical characteristics and outcome of treatment of Brazilian women with breast cancer treated at public and private institutions - the AMAZONE project of the Brazilian Breast Cancer Study Group (GBECAM). Cancer Res. 69(3 Suppl.), (2009) (Abstract 3082).
12. Nurena CR. [Incorporation of an intercultural approach in the Peruvian health care system: the vertical birth method]. Rev. Panam. SaludPublica. 26(4), 368-376(2009).
13. Argote L, Toledo GP, Delgado R et al Factores de riesgo del cancer de mama en pacientes diagnosticadas en el hospital Julio Trigo. Revista Cubana de Saludy Trabajo 11(1), 3-6(2010).
14. Pazdur R, Douillard JY, Skillings JR et al Multicenter Phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18(Suppl.), (1999) (Abstract 1009).
15. Carmichael J, Popiela T, Radstone S et al Randomized comparative study of ORZEL (oral uracil/tegafur [UFT] plust leucovorin [LV]) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18(Suppl.), (1999) (Abstract 1015).
16. Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J. Clin. Oncol. 16(10), 3461-3475 (1998).
17. Carmichael J, Popiela T, Radstone D et al Randomized comparative study of tegafur/ uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3617-3627 (2002).
18. Bourdeanu L, Wong SF. Supporting Asian patients with metastatic breast cancer during ixabepilone therapy. Expert Opin. Drug Saf. 9(3), 383-396 (2010).
19. Yip CH. Breast cancer in Asia. Methods Mol. Biol. 471, 51-64 (2009).
20. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 24(14), 2158-2163 (2006).
21. Hotta K, Kiura K, Toyooka S et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol. 2(7), 632-637 (2007).
22. Haller DG, Cassidy J, Clarke SJ et al Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol. 26(13), 2118-2123 (2008).
23. Beith JM, Goh BC, Yeo W et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc. Am. Soc. Clin. Oncol. 21(Suppl.), (2002) (Abstract 252).
24. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with an historic Western series. Radiother. Oncol. 62(2), 185-189 (2002).
25. Goel S, Cohen M, Comezoglu SN et al The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin. Cancer Res. 14(9), 2701-2709 (2008).
26. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 22(10), 2015-2025 (2004).
27. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10(4), 1289-1298 (2004).
28. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45(3), 253-285 (2006).
29. Aghajanian C, Burns HA 3rd, Jones S et al Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol. 25(9), 1082-1088 (2007).
30. Shimizu T, Yamamoto N, Yamada Y et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother. Pharmacol. 61(5), 751-758(2008).
31. Cohen M, Mould D, Roy A, Mandava M, Pfister M. A population pharmacokinetic analysis of ixabepilone in patients with cancer. J. Clin. Oncol. 26(Suppl. 15), (2008) (Abstract 2521).
32. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13(12) 1207-1223 (2008).
33. Shen H, Lee FY, Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for p-glycoprotein (P-gp/MDRl/ABCBl) but not breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol Exp. Ther. DOI: 10.1124/ jpet.110.175604 (2011) (Epub ahead of print).
34. Thomas ES, Gomez HL, Li RK et al Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol 25(33), 5210-5217(2007).
35. Sparano JA, Vrdoljak E, Rixe O et al Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28(20), 3256-3263(2010).
36. Hortobagyi GN, Gomez HL, Li RK et al Analysis of overall survival from a Phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res. Treat. 122(2), 409-418 (2010).
37. Pivot XB, Li RK, Thomas ES etal. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur. J. Cancer45(17), 2940-2946 (2009).
38. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/ HER2-negative (triple-negative) breast cancer. Breast Cancer Res. Treat. 121(2), 261-271 (2010).
39. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol 25(23), 3407-3414 (2007).
40. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 25(23), 3421-3427 (2007).
41. Roche H, Yelle L, Cognetti F etal. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25(23), 3415-3420 (2007).
42. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. 23(12), 2726-2734 (2005).
43. Thomas E, Tabernero J, Former M et al Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25(23), 3399-3406 (2007).
44. BaselgaJ, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 27(4), 526-534 (2009).
45. Fisher B, Brown A, Mamounas E et al Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15, 2483-2493 (1997).
46. Gradishar WJ. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology. 11(Suppl. 8), 15-18 (1997).
47. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol. 17, 3412-3417 (1999).
48. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br. J. Cancer 88, 1339-1345 (2003).
49. Estevez LG, Cuevas JM, Anton A et al Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a Phase II, multicenter study. Clin. Cancer Res. 9, 686-692 (2003).
50. Moulder S, Li H, Wang M etal. A Phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res. Treat 119(3), 663-671 (2010).
51. Melemed AS, O'Shaughnessy J, Nag S et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. Proceedings of: ASCO Breast Cancer Symposium. San Francisco, CA, USA, 7-8 September 2007 (Abstract 150).
52. O'Shaughnessy J, Miles D, Vukelja S et al Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 20,2812-2823 (2002).
53. Miles D, Chan A, Romieu G et al Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol. 26(Suppl.), (2008) (Abstract LBA1011).
54. Geyer CE, Forster J, Lindquist D et al Lapadnib plus capecitabine for HER2-positive advanced breast cancer. J. Engl. J. Med. 355, 2733-2743 (2006).
55. von Minckwitz G, Zielinski C, Maarteense E et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP Phase III study (GBG 26/BIG 3-05). J Clin. Oncol. 26(Suppl.), (2008) (Abstract 1025).
56. Rugo HS, Campone M, Amadori D et al Randomized Phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J. Clin. Oncol. 28(15 Suppl.), (2010) (Abstract 1040).
57. Watanabe J, Horiguchi J, Masuda N, et al Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28(15 Suppl.), (2010) (Abstract el3095).
58. Wang J, Fan Y, Xu B. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother. Pharmacol. 66(3), 597-603 (2010).
59. SO Fein L, Crocamo Ventilari Da Costa S, Gomez H etal. Analysis of Latin American cohort of two large Phase III studies of ixabepilone plus capecitabine in patients with metastatic breast cancer. Presented at: ASCO Breast Cancer Symposium. San Francisco, CA, USA, 8 October 2009 (Abstract 193).
60. Perez E, Pivot X, Vrdoljak E et al. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res. 69(Suppl. 2), (2008) (Abstract 6140).
61. Valero V, Bosserman LD, Yardley DA et al. Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): a retrospective analysis of pooled data from two Phase III clinical studies (046/048). J. Clin. Oncol. 28(Suppl. 14), (2010) (Abstract 1051).